1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Iran Pharmaceuticals and Healthcare Report Q4 2016

Iran Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 98 pages

Includes 3 FREE quarterly updates

BMI View:

The removal of economic sanctions heralds an era of uncertainty for Iran's pharmaceuticalmarket. Underlying issues regarding the operating environment will prevent an immediate uptick inmultinational drugmaker interest; rather, this will be a gradual process. Nevertheless, there has been anotable boost in international cooperation with European counterparts in particular over the past sixmonths. This will support the Iranian government's aim to attract greater direct investment from foreignpharmaceutical companies.

Headline Expenditure Projections


- Pharmaceuticals: IRR69.55trn (USD1.93bn) in 2015 to IRR79.49trn (USD1.99bn) in 2016; +14.3% inlocal currency terms and +2.9% in US dollar terms. Forecast downgraded from previous quarter.

- Healthcare: IRR800.60trn (USD22.24bn) in 2015 to IRR900.81trn (USD22.52bn) in 2016; +12.5% inlocal currency terms and +1.3% in US dollar terms. Forecast upgraded from previous quarter.

Table Of Contents

Iran Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Iran 2014-2020) 7
SWOT 9
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2012-2020) 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020) 19
Prescription Drug Market Forecast 20
Patented Drug Market Forecast 22
Generic Drug Market Forecast 23
OTC Medicine Market Forecast 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Iran 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2014-2020) 28
Industry Risk/Reward Index 29
Middle East and Africa Risk/Reward Index - Q4 2016 29
Iran Risk/Reward Index 37
Rewards 37
Risks 38
Regulatory Review 39
Intellectual Property Issues 41
Pricing and Reimbursement Regime 43
Market Overview 45
Healthcare Sector 46
Table: Healthcare Resources (Iran 2010-2015) 49
Table: Healthcare Personnel (Iran 2010-2015) 49
Table: Healthcare Activity (Iran 2010-2015) 50
Research and Development 53
Clinical Trials 55
Epidemiology 56
Competitive Landscape 60
Research-Based Industry 60
Table: Multinational Company Activity 64
Generic Drugmakers 65
Table: Leading Drug Manufacturers, Iran - To March 2009 65
Pharmaceutical Distribution 68
Table: Leading Distributors, Iranian - Year To March 20 2008 69
Pharmaceutical Retail Sector 70
Table: Tehran Stock Exchange - Listed Pharmaceutical Companies As Of November 2015 70
Company Profile 72
Caspian Tamin Pharmaceutical Company 72
Darou Pakhsh 76
Exir Pharmaceuticals 79
Pars Darou 82
Zahravi Pharmaceutical Company 84
Demographic Forecast 87
Table: Population Headline Indicators (Iran 1990-2025) 88
Table: Key Population Ratios (Iran 1990-2025) 88
Table: Urban/Rural Population and Life Expectancy (Iran 1990-2025) 89
Table: Population By Age Group (Iran 1990-2025) 89
Table: Population By Age Group % (Iran 1990-2025) 90
Glossary 92
Methodology 94
Pharmaceutical Expenditure Forecast Model 94
Healthcare Expenditure Forecast Model 94
Notes On Methodology 95
Risk/Reward Index Methodology 96
Index Overview 97
Table: Pharmaceutical Risk/Reward Index Indicators 97
Indicator Weightings 98

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.